USING GENETICALLY ENGINEERED BIOLOGICAL DRUGS (GEBD) IN TREATMENT OF SEVERE FORMS OF JUVENILE CHRONIC ARTHRITIS

In recent years significant progress has been achieved in juvenile chronic arthritis treatment due to the use of genetically engineered biological drugs. The results of the use of infliximab, adalimumab, tocilizumab, rituximab in children with severe forms of joint diseases aged from 1 to 17 years are given in the article. It has been established that the use of biological drugs significantly reduces the inflammatory process activity, contributes to remission and improves the prognosis of the disease.